Vaccines 2014, 2(1), 89-106; doi:10.3390/vaccines2010089
Review

Recent Developments in Preclinical DNA Vaccination

1 Department of Molecular Biodefense Research, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa Prefecture 236-0004, Japan 2 Choju Medical Institute, Toyohashi, Aichi Prefecture 441-8124, Japan 3 Vaccine Institute, Yokohama, Kanagawa Prefecture 2235-0045, Japan
* Author to whom correspondence should be addressed.
Received: 15 October 2013; in revised form: 22 November 2013 / Accepted: 26 November 2013 / Published: 13 January 2014
(This article belongs to the Special Issue DNA Vaccines)
PDF Full-text Download PDF Full-Text [381 KB, uploaded 13 January 2014 09:00 CET]
Abstract: The advantages of genetic immunization of the new vaccine using plasmid DNAs are multifold. For example, it is easy to generate plasmid DNAs, increase their dose during the manufacturing process, and sterilize them. Furthermore, they can be stored for a long period of time upon stabilization, and their protein encoding sequences can be easily modified by employing various DNA-manipulation techniques. Although DNA vaccinations strongly increase Th1-mediated immune responses in animals, several problems persist. One is about their weak immunogenicity in humans. To overcome this problem, various genetic adjuvants, electroporation, and prime-boost methods have been developed preclinically, which are reviewed here.
Keywords: DNA vaccine; genetic adjuvants; electroporation

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Okuda, K.; Wada, Y.; Shimada, M. Recent Developments in Preclinical DNA Vaccination. Vaccines 2014, 2, 89-106.

AMA Style

Okuda K, Wada Y, Shimada M. Recent Developments in Preclinical DNA Vaccination. Vaccines. 2014; 2(1):89-106.

Chicago/Turabian Style

Okuda, Kenji; Wada, Yoshiyuki; Shimada, Masaru. 2014. "Recent Developments in Preclinical DNA Vaccination." Vaccines 2, no. 1: 89-106.

Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert